Nontuberculous mycobacteria are ubiquitous and are usually found in soil, natural and treated water sources. They are relatively uncommon cause of pulmonary disease and likely to cause disseminated disease.
May cause both asymptomatic infection and symptomatic disease in humans.
There is no evidence of animal-to-human or human-to-human transmission in immunocompetent hosts.
Nontuberculous mycobacterial pulmonary disease is a generally slowly progressive infection.
Signs and symptoms are generally nonspecific.
A daily triple-drug regimen containing clarithromycin, rifampin and ethambutol for the treatment of nodular/bronchiectatic mycobacterium avium complex (MAC) lung disease produces a relatively high response rate similar to that seen in previous reports, as shown in a retrospective study from Japan.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Respirology - Malaysia digital copy today!
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.